Infectiology
Emerging EvidenceHow bacterial biofilms protect persistent infections and strategies to disrupt them.
An evidence-based review of emerging repurposed-drug protocols—dapsone, disulfiram, and azlocillin—targeting Borrelia persister cells in chronic Lyme disease.
Comparing lumbrokinase and nattokinase for fibrin clearance, biofilm disruption, post-COVID microclots, and cardiovascular health — with clinical dosing guidance.
A physician-led comparison of serrapeptase and nattokinase: mechanisms, clinical evidence, dosing, and which fibrinolytic enzyme fits your health goals.
A physician's guide to serrapeptase: how this proteolytic enzyme reduces inflammation, breaks down biofilm, and compares to NSAIDs — with evidence-based dosing.
Lumbrokinase is a potent fibrinolytic enzyme with emerging evidence for post-COVID microclots, Lyme biofilms, and chronic inflammation. A physician's clinical overview.
How ozone therapy works against Borrelia and co-infections, which protocols are used clinically, and what published evidence says about its role in Lyme care.
How bacterial biofilms reduce antibiotic efficacy by 100-1,000x, why standard treatment courses miss persistent infections, and what integrative approaches add.
How proteolytic enzymes nattokinase and serrapeptase degrade biofilm matrix components — mechanism, dosing, evidence, and clinical considerations.
A clinical overview of biofilm disruption strategies for persistent Lyme disease — the three-phase approach of disrupt, kill, and clear.
How LL-37 disrupts Borrelia biofilms in chronic Lyme disease. Mechanism, preclinical evidence, protocol context, and clinical observations.
How biofilms protect chronic infections from antibiotics and the immune system. Disruption strategies and clinical implications.
